Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Neoadjuvant Axitinib Effective in Subgroup of Patients with Renal Cell Carcinoma

May 16th 2022

Neoadjuvant axitinib facilitated partial nephrectomy in patients with clear cell renal cell carcinoma and complex masses with an imperative indication for nephron-sparing surgery but no viable pathway to receive the procedure.

Dr. Spiess on Key Updates in the Management of Penile Cancer

May 15th 2022

Philippe E. Spiess, MD, MS, FACS, shares key updates in the management of patients with penile cancer.

Dr. Vaishampayan on the Design of the PROBE Trial in RCC

May 13th 2022

Ulka Nitin Vaishampayan, MBBS, discusses the design of the phase 3 PROBE trial in advanced renal cell carcinoma.

Cabozantinib Plus Nivolumab Shows Efficacy in Papillary Non–Clear Cell RCC

May 11th 2022

The combination of cabozantinib plus nivolumab demonstrated promising objective response rates in patients with non–clear cell renal cell carcinoma with prominent papillary features.

Treatment Options in the Second-Line and Beyond in Advanced RCC

May 11th 2022

Drs Zhang and Ornstein discuss regimens for advanced clear-cell RCC in the second-line setting and beyond, focusing on the METEOR, CABOSEQ,TIVO-3 CHeckMate 025, and AXIS trials.

The Impact of Neoadjuvant Therapy on Treatment Selection in Advanced RCC

May 11th 2022

Dr Ornstein describes how the choice of neoadjuvant therapy can impact subsequent treatment selection in advanced RCC.

ARO-HIF2 Lowers HIF2α Expression and Demonstrates Favorable Safety Profile in Clear Cell RCC

May 4th 2022

The investigational RNA interference therapy, ARO-HIF2, reduced levels of hypoxia inducible factor-2 alpha expression and had acceptable tolerability when used in patients with clear cell renal cell carcinoma, according to data from the phase 1b AROHIF21001 trial.

The Future of Advanced Renal Cell Carcinoma Management

May 4th 2022

Drs Sumeet Bhatia and Eric Jonasch highlight unmet needs in advanced renal cell carcinoma and share clinical pearls.

Using Cabozantinib + Nivolumab to Treat Advanced Renal Cell Carcinoma

May 4th 2022

A discussion on the use of cabozantinib-nivolumab for the treatment of advanced renal cell carcinoma.

Patient Profile Presentation: A 72-Year-Old Man Presenting with Hematuria

May 4th 2022

Dr Shawnta Anakwah presents the patient profile of a 72-year-old man with advanced renal cell carcinoma presenting with hematuria.

Ongoing Clinical Trials in the Neoadjuvant Setting in RCC

May 4th 2022

Pedro Barata, MD, MSc, provides a brief overview of ongoing trials in the neoadjuvant setting in patients with RCC.

Ongoing Clinical Trials in the Adjuvant Setting in RCC

May 4th 2022

Dr Bilen reviews some ongoing trials looking into monotherapy and combination therapies in the adjuvant setting in RCC.

Adverse Events in IO-IO Combination Treatment Regimens for Advanced RCC

May 2nd 2022

Key opinion leaders discuss the common adverse events seen with IO/IO combination regimens and how to treat patients with brain metastases.

Approved First-Line IO-IO Combination Treatment Regimens for Advanced RCC

May 2nd 2022

A review of the first-line IO/IO combination regimens available for advanced RCC.

Impact of Adjuvant Therapy on Treatment Selection in Advanced RCC

April 27th 2022

David Braun, MD, touches on how the choice of adjuvant therapy can impact subsequent treatment selection in advanced RCC.

Adjuvant Systemic Therapies for Patients With RCC Post-Nephrectomy

April 27th 2022

Dr Zhang discusses recently approved adjuvant systemic therapy for patients with RCC who have a high risk of recurrence after nephrectomy.

Nemvaleukin Alone and in Combination with Pembrolizumab Produces Efficacy in Advanced RCC

April 26th 2022

The IL-2 variant immunotherapy nemvaleukin alfa elicited responses and demonstrated safety as a single agent and in combination with pembrolizumab in patients with advanced renal cell carcinoma.

Renal Cell Carcinoma: Future Directions in Care

April 22nd 2022

Looking toward the future management of renal cell carcinoma, experts consider treatment strategies for bone metastasis, brain metastasis, and VHL disease.

Non–Clear Cell RCC: Clinical Rationale Behind Therapy

April 22nd 2022

A brief review of the clinical rationale behind therapeutic regimens used for patients with non-clear cell carcinoma.

PROBE Trial in Progress to Understand Potential Benefits of Cytoreductive Nephrectomy in Metastatic RCC

April 20th 2022

Ulka Nitin Vaishampayan, MBBS, discusses the intent of the PROBE trial, as well as updates regarding the KEYNOTE-564 trial and novel agents in kidney cancer treatment.